术前血小板与淋巴细胞比值对肝细胞癌患者预后影响的Meta分析

李志斌; 肖冬生; 宋伟

doi:10.3969/j.issn.1001-5256.2017.09.021

术前血小板与淋巴细胞比值对肝细胞癌患者预后影响的Meta分析

DOI: 10.3969/j.issn.1001-5256.2017.09.021

1. 江西省共青城市人民医院普通外科
2. 南昌大学第二附属医院肝胆外科

详细信息

中图分类号: R735.7
计量
- 文章访问数: 1858
- HTML全文浏览量: 9
- PDF下载量: 423
- 被引次数: 0
出版历程
- 收稿日期: 2017-03-27
- 出版日期: 2017-09-20

Prognostic value of preoperative platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma: a Meta-analysis

Department of General Surgery, Gongqingcheng People's Hospital

摘要

摘要: 目的系统评价术前外周血血小板/淋巴细胞比值(PLR)对肝细胞癌(HCC)患者预后的影响。方法计算机检索Medline、EMBASE、Cochrane Library、中国知网、中国生物医学文献数据库、维普及万方数据库,收集关于术前PLR与HCC预后相关性的研究。检索时限截至2017年1月,由2名研究者根据纳入与排除标准对文献进行独立筛选、提取资料和评价质量后,采用RevMan5.3软件进行Meta分析,各研究间的异质性分析采用χ~2检验。结果纳入符合标准的文献18篇,共4193例患者。Meta分析结果显示,高PLR组患者的总生存率明显低于低PLR组[HR=1.74,95%可信区间(95%CI):1.42~2.14,P<0.001],高PLR组患者的无瘤生存率或无复发生存率明显低于低PLR组(HR=1.76,95%CI:1.56~1.98,P<0.001)。亚组分析结果显示,在种族(亚洲人、高加索人)、治疗方法(手术、化疗、综合治疗)、样本量(≥200、<200)、PLR截断值(≥150、<150)及NOS评分(≥7、<7)等方面,高PLR组患者均明显低于低...
- 肝肿瘤 /
- 血小板与淋巴细胞比值 /
- 预后 /
- Meta分析
Abstract: Objective To systematically investigate the prognostic value of preoperative platelet-to-lymphocyte ratio ( PLR) in patients with hepatocellular carcinoma ( HCC) . Methods Medline, EMBASE, Cochrane Library, CNKI, CBM, VIP, and Wanfang Data were searched for studies assessing the association between preoperative PLR and prognosis of HCC published up to January 2017. Two reviewers independently screened the articles according to the inclusion and exclusion criteria, extracted data, and assessed methodological quality, and then a meta-analysis was performed using Rev Man 5. 3 software. The chi-square test was used for the analysis of heterogeneity between studies. Results A total of 18 articles with 4193 patients were included. The meta-analysis showed that compared with those with low PLR, patients with high PLR had significantly lower overall survival ( OS) rate ( hazard ratio [HR]= 1. 74, 95% confidence interval[CI]1. 42-2. 14, P < 0. 001) and disease-free survival rate or relapse-free survival rate ( HR = 1. 76, 95% CI: 1. 56-1. 98, P <0. 001) . The subgroup analysis revealed that patients with high PLR had significantly shorter OS than those with low PLR, regardless of race ( Asian or Caucasian) , treatment method ( surgery, chemotherapy, or multimodality therapy) , sample size ( ≥200 or < 200) , cut-off value of PLR ( ≥150 or < 150) , and NOS score ( ≥7 or < 7) ( all P < 0. 05) . Conclusion High preoperative PLR is closely associated with poor prognosis of HCC patients, suggesting that PLR might be a prognostic factor in HCC patients.
- liver neoplasms /
- platelet to lymphocyte ratio /
- prognosis /
- Meta-analysis

HTML全文

参考文献(43)

[1]SIEGEL R, NAISHADHAM D, JEMAL A.Cancer statistics, 2013[J].CA Cancer J Clin, 2013, 63 (1) :11-30.

[2]BRUIX J, SHERMAN M.Management of hepatocellular carcinoma:an update[J].Hepatology, 2011, 53 (3) :1020-1022.

[3]GRIVENNIKOV SI, GRETEN FR, KARIN M.Immunity, inflammation, and cancer[J].Cell, 2010, 140 (6) :883-899.

[4]ZHANG TT, ZHAO XQ, LIU Z, et al.Preoperative neutrophillymphocyte ratio is an independent prognostic factor for hepatocellular carcinoma after radical resection[J].J Clin Hepatol, 2015, 31 (6) :927-931. (in Chinese) 张婷婷, 赵向前, 刘哲, 等.术前中性粒细胞与淋巴细胞比值对行根治性切除术的肝细胞癌患者预后的影响[J].临床肝胆病杂志, 2015, 31 (6) :927-931.

[5]WANG XB, GAO FY, LIU Y.Neutrophil-lymphocyte ratio:a novel predictor of clinical outcome of patients with hepatocellular carcinoma[J].J Clin Hepatol, 2016, 32 (4) :649-652. (in Chinese) 王宪波, 高方媛, 刘尧.中性粒细胞与淋巴细胞比值:一项评价肝细胞癌患者预后的新指标[J].临床肝胆病杂志, 2016, 32 (4) :649-652.

[6]SZKANDERA J, STOTZ M, ABSENGER G, et al.Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients[J].Br J Cancer, 2014, 110 (1) :183-188.

[7]QI Q, GENG Y, SUN M, et al.Clinical implications of systemic inflammatory response markers as independent prognostic factors for advanced pancreatic cancer[J].Pancreatology, 2015, 15 (2) :145-150.

[8]LABELLE M, BEGUM S, HYNES RO.Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis[J].Cancer Cell, 2011, 20 (5) :576-590.

[9]LABELLE M, BEGUM S, HYNES RO.Platelets guide the formation of early metastatic niches[J].Proc Natl Acad Sci U S A, 2014, 111 (30) :e3053-e3061.

[10]GU X, GAO XS, CUI M, et al.Clinicopathological and prognostic significance of platelet to lymphocyte ratio in patients with gastric cancer[J].Oncotarget, 2016, 7 (31) :49878-49887.

[11]ASANO Y, KASHIWAGI S, ONODA N, et al.Platelet-lymphocyte ratio as a useful predictor of the therapeutic effect of neoadjuvant chemotherapy in breast cancer[J].PLo S One, 2016, 11 (7) :e0153459.

[12]YOU J, ZHU GQ, XIE L, et al.Preoperative platelet to lymphocyte ratio is a valuable prognostic biomarker in patients with colorectal cancer[J].Oncotarget, 2016, 7 (18) :25516-25527.

[13]KABIR T, MOHD NOOR NA, JUNNARKAR SP, et al.Does preoperative platelet-lymphocyte ratio or prognostic nutritional index predict survival after surgical resection for hepatocellular carcinoma?[J].HPB, 2016, 18:e709-e710.

[14]PENG W, LI C, ZHU WJ, et al.Prognostic value of the platelet to lymphocyte ratio change in liver cancer[J].J Surg Res, 2015, 194 (2) :464-470.

[15]PARMAR MK, TORRI V, STEWART L.Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints[J].Stat Med, 1998, 17 (24) :2815-2834.

[16]TIERNEY JF, STEWART LA, GHERSI D, et al.Practical methods for incorporating summary time-to-event data into meta-analysis[J].Trials, 2007, 8:16.

[17]PINATO DJ, STEBBING J, ISHIZUKA M, et al.A novel and validated prognostic index in hepatocellular carcinoma:the inflammation based index (IBI) [J].J Hepatol, 2012, 57 (5) :1013-1020.

[18]NEOFYTOU K, SMYTH EC, GIAKOUSTIDIS A, et al.Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor[J].Med Oncol, 2014, 31 (10) :239.

[19]SUN Q, JIAO SC, WU JY, et al.Pretreatment haematological laboratory values:the new prognostic factors in patients undergoing hepatectomy for hepatocellular carcinoma[J].Biomed Res, 2014, 25 (4) :580-587.

[20]LI X, CHEN ZH, XING YF, et al.Platelet-to-lymphocyte ratio acts as a prognostic factor for patients with advanced hepatocellular carcinoma[J].Tumour Biol, 2015, 36 (4) :2263-2269.

[21]CHAN AW, CHAN SL, WONG GL, et al.Prognostic Nutritional Index (PNI) predicts tumor recurrence of very early/early stage hepatocellular carcinoma after surgical resection[J].Ann Surg Oncol, 2015, 22 (13) :4138-4148.

[22]FAN W, ZHANG Y, WANG Y, et al.Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictors of survival and metastasis for recurrent hepatocellular carcinoma after transarterial chemoembolization[J].PLo S One, 2015, 10 (3) :e0119312.

[23]LI X, HAN Z, CHENG Z, et al.Clinical significance of preoperative platelet-to-lymphocyte ratio in recurrent hepatocellular carcinoma after thermal ablation:a retrospective analysis[J].Int J Hyperthermia, 2015, 31 (7) :758-763.

[24]NI XC, YI Y, FU YP, et al.Prognostic value of the modified glasgow prognostic score in patients undergoing radical surgery for hepatocellular carcinoma[J].Medicine (Baltimore) , 2015, 94 (36) :e1486.

[25]WANG Q, BLANK S, FIEL MI, et al.The severity of liver fibrosis influences the prognostic value of inflammation-based scores in hepatitis B-associated hepatocellular carcinoma[J].Ann Surg Oncol, 2015, 22 (Suppl 3) :s1125-s1132.

[26]XIA W, KE Q, WANG Y, et al.Predictive value of pre-transplant platelet to lymphocyte ratio for hepatocellular carcinoma recurrence after liver transplantation[J].World J Surg Oncol, 2015, 13:60.

[27]XUE TC, JIA QA, GE NL, et al.The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization[J].Tumour Biol, 2015, 36 (8) :6045-6051.

[28]AINO H, SUMIE S, NIIZEKI T, et al.The systemic inflammatory response as a prognostic factor for advanced hepatocellular carcinoma with extrahepatic metastasis[J].Mol Clin Oncol, 2016, 5 (1) :83-88.

[29]D'EMIC N, ENGELMAN A, MOLITORIS J, et al.Prognostic significance of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients treated with selective internal radiation therapy[J].J Gastrointest Oncol, 2016, 7 (2) :269-277.

[30]GOH BK, KAM JH, LEE SY, et al.Significance of neutrophil-tolymphocyte ratio, platelet-to-lymphocyte ratio and prognostic nutrition index as preoperative predictors of early mortality after liver resection for huge (>/=10 cm) hepatocellular carcinoma[J].J Surg Oncol, 2016, 113 (6) :621-627.

[31]JI F, LIANG Y, FU SJ, et al.A novel and accurate predictor of survival for patients with hepatocellular carcinoma after surgical resection:the neutrophil to lymphocyte ratio (NLR) combined with the aspartate aminotransferase/platelet count ratio index (APRI) [J].BMC Cancer, 2016, 16:137.

[32]TIAN XC, LIU XL, ZENG FR, et al.Platelet-to-lymphocyte ratio acts as an independent risk factor for patients with hepatitis B virus-related hepatocellular carcinoma who received transarterial chemoembolization[J].Eur Rev Med Pharmacol Sci, 2016, 20 (11) :2302-2309.

[33]SU ZJ, ZHAI JW, PAN QX, et al.Relationship between platelet-to-lymphocyte ratio and prognosis in patients with hepatocellular carcinom[J].Chin J Gen Surg, 2016, 25 (1) :12-18. (in Chinese) 苏子剑, 翟军伟, 潘群雄, 等.术前血小板/淋巴细胞比值与肝癌预后的关系[J].中国普通外科杂志, 2016, 25 (1) :12-18.

[34]PERZ JF, ARMSTRONG GL, FARRINGTON LA, et al.The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide[J].J Hepatol, 2006, 45 (4) :529-538.

[35]SIDERAS K, KWEKKEBOOM J.Cancer inflammation and inflammatory biomarkers:can neutrophil, lymphocyte, and platelet counts represent the complexity of the immune system?[J].Transpl Int, 2014, 27 (1) :28-31.

[36] MANTOVANI A, ALLAVENA P, SICA A, et al.Cancer-related inflammation[J].Nature, 2008, 454 (7203) :436-444.

[37]WANG G, LU X, DEY P, et al.Targeting YAP-dependent MD-SC infiltration impairs tumor progression[J].Cancer Discov, 2016, 6 (1) :80-95.

[38]MANTOVANI A, ROMERO P, PALUCKA AK, et al.Tumour immunity:effector response to tumour and role of the microenvironment[J].Lancet, 2008, 371 (9614) :771-783.

[39]NIESWANDT B, HAFNER M, ECHTENACHER B, et al.Lysis of tumor cells by natural killer cells in mice is impeded by platelets[J].Cancer Res, 1999, 59 (6) :1295-1300.

[40]SIERKO E, WOJTUKIEWICZ MZ.Platelets and angiogenesis in malignancy[J].Semin Thromb Hemost, 2004, 30 (1) :95-108.

[41]MAN YG, STOJADINOVIC A, MASON J, et al.Tumor-infiltrating immune cells promoting tumor invasion and metastasis:existing theories[J].J Cancer, 2013, 4 (1) :84-95.

[42]WADA Y, NAKASHIMA O, KUTAMI R, et al.Clinicopathological study on hepatocellular carcinoma with lymphocytic infiltration[J].Hepatology, 1998, 27 (2) :407-414.

[43] SCHREIBER RD, OLD LJ, SMYTH MJ.Cancer immunoediting:integrating immunity's roles in cancer suppression and promotion[J].Science, 2011, 331 (6024) :1565-1570.

施引文献

资源附件(0)

访问统计